Clinical Trials Sponsored by Janssen Biotech, Inc.

Total 494 results

Janssen Biotech, Inc.

Completed

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Psoriasis
Janssen Biotech, Inc.

Terminated

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) (REGAIN)

Arthritis, Rheumatoid

United States, Canada
Janssen Biotech, Inc.

Completed

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR)

Psoriasis

United States
Janssen Biotech, Inc.

Terminated

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Crohn's Disease

United States, France, United Kingdom, Germany, Belgium, Australia, Israel, Canada, Netherlands, New Zealand, Czech Republic, Austria, Poland, Hungary
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
Janssen Biotech, Inc.

Completed

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Rheumatoid Arthritis | Arthritis, Psoriatic | Ankylosing Spondylitis
Janssen Biotech, Inc.

Completed

The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry (TREAT)

Crohn's Disease
Janssen Biotech, Inc.

Active, not recruiting

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Prostate Cancer | Prostatic Neoplasm

United States
Janssen Biotech, Inc.

Active, not recruiting

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Ulcerative Colitis

United States, France, Germany, Spain, Canada, Greece, Korea, Republic of, Austria, Czechia
Janssen Biotech, Inc.

Completed

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis (SpA23)

Spondyloarthritis

France
Institut Pasteur
Janssen Biotech, Inc.

Recruiting

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis (Pso23)

Psoriasis

France
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Withdrawn

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. (INSPIRE-CKD)

Hypertension | Renal Insufficiency, Chronic
Bristol-Myers Squibb
Janssen Biotech, Inc.

Completed

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Advanced Cancer

United States, Switzerland, France, Puerto Rico, Italy, Germany, Australia, Canada, Spain
Janssen-Ortho Inc., Canada
Ortho Biotech Canada

No longer available

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Multiple Myeloma

Canada
Janssen Biotech, Inc.
Merck Sharp & Dohme LLC

Completed

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Autoimmune Diseases | Arthritis | Arthritis, Rheumatoid

United States, United Kingdom, Belgium, Greece, Canada, Germany, Sweden, Austria
Janssen Biotech, Inc.
Merck Sharp & Dohme LLC

Completed

Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis

Inflammatory Bowel Disease
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Barry A. Boilson
Janssen Biotech, Inc.

Enrolling by invitation

Daratumumab in HLA Desensitization Prior to Transplantation

Cardiac Transplant

United States
University of California, San Francisco
Janssen Biotech, Inc.

Recruiting

Guselkumab Immunogenetics (TIG)

Plaque Psoriasis | Psoriasis Guttate

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Healthy Subjects | Pharmacokinetics of ASP015K

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

Healthy Subjects | Pharmacokinetics of ASP015K

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy Subjects | Bioavailability of ASP015K | Pharmacokinetics of ASP015K | Food Effect of ASP015K

United States
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Colombia, Czechia, Hungary, Mexico, Poland
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

Healthy Volunteers | Pharmacokinetics of ASP015K

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
Janssen Inc.

Completed

Golimumab for Adherence in Rheumatoid Arthritis (GO FAR)

Arthritis, Rheumatoid

Canada
Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada
Janssen Inc.

Completed

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting (COSMiC)

Prostatic Neoplasms

Canada
Janssen Inc.

Completed

Biologic Treatment Registry Across Canada (BioTRAC)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis, Axial

Canada
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Janssen Inc.

Terminated

Observational Study of Golimumab Intravenous Infusion (GO-IV)

Rheumatoid Arthritis

Canada
Janssen Inc.

Completed

A Study of Participants With Advanced Prostate Cancer in Canada (GURC)

Prostatic Neoplasms

Canada
Janssen Inc.

Completed

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CanCARE)

Diabetes Mellitus, Type 2

Canada
Janssen Inc.

Completed

An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis (PROSTARRT)

Chronic Kidney Disease

Canada
Janssen Inc.

Completed

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (ICE)

Crohn's Disease

Canada
Janssen Inc.

Completed

Remicade Infusion Management Program (RemiTRAC)

Arthritis, Rheumatoid | Crohn Disease

Canada
VivaVision Biotech, Inc

Recruiting

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Inflammation

United States
Krystal Biotech, Inc.

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (Serpentine-1)

Alpha 1-Antitrypsin Deficiency

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Cancer | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Osteosarcoma | Cutaneous Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Krystal Biotech, Inc.

Not yet recruiting

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Autosomal Recessive Ichthyosis

United States
Krystal Biotech, Inc.

Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Johnpro Biotech, Inc.

Recruiting

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Glioblastoma

Taiwan
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States

Clinical Trials Sponsored by Janssen Biotech, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations